Fig. 4
From: Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
Efficacy evaluation of immunotherapy (anti-PD-L1 and/or anti-TIGIT) and different fractionation schemes of radiotherapy (RT) in CT26 model. Induction of the expression of PD-L1 (cd274 gene) (a) or TIGIT (b) using RNA sequencing analysis (left) (7 days after the beginning of RT and 7 days after the end of RT for the 18x2Gy scheme) and flow cytometry monitoring (FCM) (right) (7, 14 days after the beginning of RT and 7 days after the end of RT (day 30) for the 18x2Gy scheme): control (black), 1×16.4Gy (red), 3x8Gy (blue), 18x2Gy (purple). Growth of irradiated tumors in mice treated with 0Gy, 1×16.4Gy, 3x8Gy, 18x2Gy with IgG or anti-PD-L1 and/or anti-TIGIT (c). Complete response (CR) ratio indicates the number of mice free from the irradiated tumor. Mean ± SEM for 18x2Gy (purple) and 3x8Gy (blue) are shown at the bottom of the Fig. X axes express the number of days since the beginning of RT. Y axes express the tumor volume (mm3). Experimental groups contained at least 8 mice per group. Not significant (NS); *p < 0.05; **p < 0.01, ***p < 0.001. Non-parametric Mann-Whitney test was used